EluNIR – BIONICS
- 5.4% target lesion failure at 12 months
- 0.4% stent thrombosis at 24 months
- 0% late stent thrombosis at 12 months
- EluNIR was found non-inferior to Resolute in a broad, less selected ‘more comers’ population
Kandzari, David E. et al. Randomized comparison of Ridaforolimus- and Zotarolimus-Eluting Coronary Stent in Patients with Coronary Artery Disease Circulation (2017) 136: 1304-1314